

Chun Li,<sup>a\*</sup> Brendan Twamley<sup>b</sup>  
and Nicholas R. Natale<sup>a</sup><sup>a</sup>Department of Chemistry, University of Idaho,  
Moscow, ID 83844-2343, USA, and <sup>b</sup>University  
Research Office, 114 Morrill Hall, University of  
Idaho, Moscow, ID 83844-3010, USA

Correspondence e-mail: li1090@uidaho.edu

## Key indicators


Single-crystal X-ray study  
 $T = 87\text{ K}$   
Mean  $\sigma(\text{C}-\text{C}) = 0.002\text{ \AA}$   
 $R$  factor = 0.035  
 $wR$  factor = 0.095  
Data-to-parameter ratio = 12.7For details of how these key indicators were  
automatically derived from the article, see  
<http://journals.iucr.org/e>.Ethyl 3-(10-chloroanthracenyl)-5-(1-phenyl-  
2-hydroxyethenyl)isoxazole-4-carboxylate: an  
enol produced by Dess–Martin oxidationThe title compound,  $\text{C}_{28}\text{H}_{20}\text{ClNO}_4$ , is a very stable enol  
produced by a Dess–Martin oxidation, not the expected  
ketone. The enol form is stabilized by intramolecular  
hydrogen bonding and the molecules associate into dimers  
*via* weak  $\text{C}-\text{H}\cdots\text{N}$  hydrogen bonding.


Received 9 November 2005

Accepted 23 January 2006

Online 31 January 2006

## Comment

During our pursuit of a structure–activity relationship study of  
a series of anticancer agents, (Verner *et al.*, 1990; Zhou *et al.*,  
1997), the title compound, (I), was produced by a Dess–Martin  
oxidation (Dess & Martin, 1983, 1991) [see Nicolaou *et al.*  
(2002, and references therein) for general reviews on appli-  
cations of Dess–Martin periodinane [DMP, 1,1,1-triacetoxy-  
1,1-dihydro-1,2-benziodoxol-3(1*H*)-one] and related hyper-  
valent iodine reagents] and its structure was characterized  
(Fig. 1).The mechanism of enol formation is proposed in the  
scheme. DMP was prepared by complete oxidation of 2-  
iodobenzoic acid, followed by acetylation of 2-iodoxybenzoic  
acid (IBX). However, if the oxidation of iodobenzoic acid is  
incomplete, an intermediate, iodosobenzoic acid, will be  
produced, which can tautomerize between an open and a  
closed form (Moss *et al.*, 1998). It is possible that the presence  
of an open form of iodosobenzoic acid facilitates the depro-  
tonation of an  $\alpha$ -hydrogen and protonation of the ketone.  
After esterification, iodosobenzoic acid will be regenerated  
through its closed form. No reaction was observed when IBX  
was used as the only catalyst in the oxidation reaction of




**Figure 1**  
Molecular structure of (I), showing 30% probability displacement ellipsoids. H atoms have been omitted for clarity.

phenethyl alcohol, nor was an enol formed when IBX was reacted with a ketone.

The enol form is stabilized by the formation of a strong intramolecular hydrogen bond (Table 1) with an O...O distance of 2.6193 (14) Å. The anthracenyl group is almost perpendicular to the isoxazole plane [85.51 (4)°], which is similar to analogous anthracenyl isoxazole structures in the Cambridge Structural Database (CSD; Version 5.27; Allen, 2002), *viz.* ethyl 3-(10'-chloro-9'-anthracenyl)-5-methyl-4-isoxazolecarboxylate (74.3°; Han *et al.*, 2003; CSD refcode EZENEC), ethyl 3-(10'-chloro-9'-anthracenyl)-5-(2-phenylethyl)-4-isoxazolecarboxylate (78.5°; Han *et al.*, 2002, and references therein; CSD refcode MUQMOA), and ethyl 3-(9-anthryl)-5-methyl-4-isoxazolecarboxylate (80.7°; Mosher *et al.*, 1996; CSD refcode TEKJIC). Unlike previous anthracenyl isoxazoles, the orientation in compound (I) allows the molecule to form weakly associated dimers *via* non-classical hydrogen bonds (Table 1) between the pendant phenyl ring and the isoxazole N atom (Fig. 2). This synthon has been reported in the isoxazole *N*-(2,6-dimethylphenyl)-5-methylisoxazole-3-carboxamide (Jaulmes *et al.* 1993; CSD refcode HABRUX) forming a three-dimensional network with phenyl C...N distances of *ca* 3.7 Å.

## Experimental

Ethyl 3-(10-chloroanthracenyl)-5-(1-hydroxy-2-phenethyl)-isoxazole-4-carboxylate (100 mg, 0.21 mmol) was added to a stirred solution of DMP (135 mg, 0.32 mmol, 1.5 equivalents) in CH<sub>2</sub>Cl<sub>2</sub> (15 ml). After 2 h, the solution was diluted with diethyl ether (50 ml) and poured into saturated aqueous NaHCO<sub>3</sub> (50 ml) containing Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> (12.5 g). The mixture was stirred for 10 min. After diethyl ether (50 ml) was added, the layers were separated. The ether layer was extracted with saturated aqueous NaHCO<sub>3</sub> (50 ml) and water (50 ml), and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration and removal of the ether by rotary evaporation was followed by recrystallization hexane–ethyl acetate (3:1) produced compound (I) as pale-yellow prisms in 98% yield (m.p. 465.5–466.0 K). <sup>1</sup>H NMR (CDCl<sub>3</sub>, p.p.m.): δ 0.053 (*t*, *J* = 7.2 Hz, 3H), 3.67 (*q*, *J* = 7.2 Hz, 2H), 6.83 (*d*, *J* = 1.5 Hz, 1H), 7.30 (*m*, 1H), 7.45 (*m*, 2H), 7.55 (*m*, 2H), 7.66 (*m*, 4H), 7.98 (*d*, *J* = 8.7 Hz, 2H), 8.63 (*d*, *J* = 8.7 Hz, 2H), 10.99 (*d*, *J* = 1.8 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, p.p.m.): δ 12.12, 62.25, 110.00, 112.75, 122.02, 125.11, 125.57, 126.83, 126.91, 127.81, 128.30, 128.48, 130.11, 131.12, 131.25, 135.04, 139.68, 160.78, 165.14, 171.68; EI–MS: 469.17 (*M*<sup>+</sup>), 350.10, 277.05, 237.05,



**Figure 2**  
Illustration of hydrogen bonding (dashed lines) in (I). Only the H atoms involved in these interactions are shown.

91.05. The desired ketone product can be obtained from the same procedure; however, the yield of ketone is variable. Fractional recrystallization using hexanes–EtOAc (3:1) resulted in a good separation of the ketone and enol mixture.

## Crystal data

C<sub>28</sub>H<sub>20</sub>ClNO<sub>4</sub>  
*M*<sub>r</sub> = 469.90  
Monoclinic, *P*2<sub>1</sub>/*n*  
*a* = 10.6621 (12) Å  
*b* = 15.5874 (17) Å  
*c* = 13.2180 (15) Å  
*β* = 92.069 (2)°  
*V* = 2195.3 (4) Å<sup>3</sup>  
*Z* = 4

*D*<sub>x</sub> = 1.422 Mg m<sup>-3</sup>  
Mo Kα radiation  
Cell parameters from 7425 reflections  
*θ* = 2.3–30.0°  
*μ* = 0.21 mm<sup>-1</sup>  
*T* = 87 (2) K  
Parallelepiped, pale yellow  
0.44 × 0.41 × 0.19 mm

## Data collection

Bruker/Siemens SMART APEX diffractometer  
*ω* scans  
Absorption correction: multi-scan (SADABS; Bruker, 2001)  
*T*<sub>min</sub> = 0.913, *T*<sub>max</sub> = 0.961  
32656 measured reflections

3975 independent reflections  
3724 reflections with *I* > 2σ(*I*)  
*R*<sub>int</sub> = 0.021  
*θ*<sub>max</sub> = 25.3°  
*h* = -12 → 12  
*k* = -18 → 18  
*l* = -15 → 15

## Refinement

Refinement on *F*<sup>2</sup>  
*R* [*F*<sup>2</sup> > 2σ(*F*<sup>2</sup>)] = 0.035  
*wR* (*F*<sup>2</sup>) = 0.095  
*S* = 1.05  
3975 reflections  
312 parameters

*w* = 1/[σ<sup>2</sup>(*F*<sub>o</sub><sup>2</sup>) + (0.0505*P*)<sup>2</sup> + 1.2473*P*]  
where *P* = (*F*<sub>o</sub><sup>2</sup> + 2*F*<sub>c</sub><sup>2</sup>)/3  
(Δ/*σ*)<sub>max</sub> = 0.001  
Δ*ρ*<sub>max</sub> = 0.29 e Å<sup>-3</sup>  
Δ*ρ*<sub>min</sub> = -0.44 e Å<sup>-3</sup>

H atoms treated by a mixture of independent and constrained refinement

**Table 1**  
Hydrogen-bond geometry (Å, °).

<i>D</i> –H... <i>A</i>	<i>D</i> –H	H... <i>A</i>	<i>D</i> ... <i>A</i>	<i>D</i> –H... <i>A</i>
C19–H19...N1 <sup>i</sup>	0.95	2.68	3.5669 (19)	156
C21–H21...N1 <sup>i</sup>	0.95	2.60	3.4849 (19)	155
O2–H2A...O3	0.86 (2)	1.77 (2)	2.6193 (14)	173 (2)

Symmetry code: (i)  $-x + 1, -y + 1, -z + 1$ .

Atom H2A was located and refined freely. All other H atoms were positioned geometrically and refined using a riding model, with  $U_{\text{iso}}(\text{H})$  constrained to be  $1.2U_{\text{eq}}$  of the carrier atom and  $\text{C}-\text{H} = 0.95-0.99 \text{ \AA}$ .

Data collection: *SMART* (Bruker, 2001); cell refinement: *SAINT-Plus* (Bruker, 2001); data reduction: *SAINT-Plus*; program(s) used to solve structure: *XS* in *SHELXTL* (Bruker, 2001); program(s) used to refine structure: *XL* in *SHELXTL*; molecular graphics: *XP* in *SHELXTL*; software used to prepare material for publication: *XCIF* in *SHELXTL*.

The Bruker (Siemens) SMART APEX diffraction facility was established at the University of Idaho with the assistance of the NSF-EPSCoR program and the M. J. Murdock Charitable Trust, Vancouver, WA, USA. The authors thank the National Institute of Neurological Disease and Stroke for grant NS 038444. CL acknowledges the support of NIH INBRE grant P20 RR16454, the Malcolm and Carol

Renfrew Scholarship Endowment of the University of Idaho, and Dr Richard Williams for helpful discussions.

## References

- Allen, F. H. (2002). *Acta Cryst.* **B58**, 380–388.
- Bruker (2001). *SMART* (Version 5.630), *SAINT-Plus* (Version 6.45a), *SADABS* (Version 2.10) and *SHELXTL* (Version 6.12). Bruker AXS Inc., Madison, Wisconsin, USA.
- Dess, D. B. & Martin, J. C. (1983). *J. Org. Chem.* **48**, 4155–4156.
- Dess, D. B. & Martin, J. C. (1991). *J. Am. Chem. Soc.* **113**, 7277–7287.
- Han, X., Li, C., Rider, K. C., Blumenfeld, A., Twamley, B. & Natale, N. R. (2002). *Tetrahedron Lett.* **43**, 7673–7677.
- Han, X., Twamley, B. & Natale, N. R. (2003). *J. Heterocycl. Chem.* **40**, 539–545.
- Jaulmes, S., Dugue, J., Agafonov, V., Ceolin, R., Cense, J. M. & Lepage, F. (1993). *Acta Cryst.* **C49**, 1007–1011.
- Mosher, M. D., Natale, N. R. & Vij, A. (1996). *Acta Cryst.* **C52**, 2513–2515.
- Moss, R. A., Vijayaraghavan, S. & Emge, T. J. (1998). *Chem. Commun.* pp. 1559–1560.
- Nicolaou, K. C., Montagnon, T., Baran, P. S. & Zhong, Y.-L. (2002). *J. Am. Chem. Soc.* **124**, 2245–2258.
- Verner, E. J., Oliver, B. J., Schlicksupp, L. & Natale, N. R. (1990). *Heterocycles*, **31**, 327–339.
- Zhou, P., Mosher, M. D., Taylor, W. D., Crawford, G. A. & Natale, N. R. (1997). *Bioorg. Med. Chem. Lett.* **7**, 2455–2456.